ArticleFrontiers in public health2026
Disease burden and health-related quality of life among adults aged 50 years or older with herpes zoster in Huzhou, China.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study assessed the disease burden and health-related quality of life (HRQoL) among adults aged 50 years and older with herpes zoster (HZ) in Huzhou, China, and identified factors associated with increased disease burden. Methods: A cross-sectional study was conducted among adults aged 50 years or older who developed HZ between 1 June 2024 and 1 June 2025 in Huzhou, China. Participants completed a structured questionnaire in September 2025 after the acute phase and retrospectively reported HRQoL during the acute HZ phase; participants with PHN also reported HRQoL during the PHN phase. Disease-burden and HRQoL distributions were compared using the Mann-Whitney U test or Kruskal-Wallis test, as appropriate. Gamma generalized linear models (GLMs) with a log link were used to identify factors associated with total, direct, and indirect burden. Results: A total of 222 participants were included, of whom 62 (27.9%) developed PHN. Costs were recorded in RMB as gross disease-related expenditures before reimbursement and converted using USD = RMB/7.1. The median direct burden was RMB 39,998.58 (P25, P75: RMB 11,792.27, 277,962.43), equivalent to USD 5,633.62 (P25, P75: USD 1,660.88, 39,149.64), and the median indirect burden was RMB 1,843.59 (USD 259.66; P25, P75: USD 155.79, 519.31). Participants with PHN had a higher median total burden than those without PHN (USD 10,958.43 vs. USD 4,740.60; Conclusion: Herpes zoster was associated with substantial disease burden and markedly impaired HRQoL among adults aged 50 years or older in Huzhou. PHN and inpatient treatment identified subgroups with particularly high burden. These regional estimates may inform prevention policy and future evaluations of HZ vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.